Market growth is driven by the rising prevalence of cancer, increasing cancer research, rising investments in regenerative medicine research, rising demand for monoclonal antibodies, and rapid growth in the biotechnology and biopharmaceutical industries.
Expected Revenue Growth:
According to the new market research report by MarketsandMarkets, the global primary cells market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960
What This Report Will Provide?
This study involved four major activities in estimating the current size of the primary cells market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.
Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Primary cells are considered to be more biologically representative in comparison to cell lines owing to their very identical characteristics to the original donor tissue. Owing to this, it is becoming increasingly evident that primary cells in 3D cell cultures are capable of producing more biologically representative models of in vivo multicellular environments as compared to cell lines. The adoption of primary cells in 3D cultures is high due to their more accurate outcomes as compared to normal cell lines.
Primary cell culture contamination is one of the most common problems encountered in cell culture laboratories. The use of contaminated cells endangers cell physiology and often leads to incorrect results or causes the loss of unique cell lines. Contamination in cell cultures not only slows down cell metabolism but can also contaminate final products such as vaccines, which can destroy the entire batch.
North America is the largest regional market for primary cells :
The global primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the primary cells market. The growth in the North American primary cells market can be attributed to the increasing number of players launching new human primary cells for research, expansion of the pharmaceutical and biotechnology industries, growing focus on R&D, and increasing prevalence of cancer in the region.
Some key players in the Human Primary Cells Market (2020- 2025)
Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sàrl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France).
Frequently Asked Questions (FAQs) :
· What are the recent trends affecting the primary cells market?
· What are the different types of primary cells used?
· Who are the key players in the primary cells market?
· Who are the key end-users of the primary cells market?
· Which region is lucrative for the primary cells market?
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain-points around revenues decisions.